CGP 35269Alternative Names: CGP35269; IFNα B/D; Interferon-alpha B/D hybrid; Interferon-alpha-1/alpha-8 hybrid; Recombinant human interferon-alpha B/D hybrid; rHu INF-alpha B/D hybrid
Latest Information Update: 26 Aug 2002
At a glance
- Originator Novartis
- Class Interferons
- Mechanism of Action Interferon alpha stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hepatitis B; HIV infections; Viral haemorrhagic fevers